Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2019 April;110(2) > Minerva Medica 2019 April;110(2):121-38

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW   

Minerva Medica 2019 April;110(2):121-38

DOI: 10.23736/S0026-4806.18.05861-5

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Cardiac resynchronization therapy: a comprehensive review

Jeremy MOSKOVITCH 1, Aleksandr VOSKOBOINIK 1, 2, 3

1 Alfred Heart Centre, Alfred Hospital, Melbourne, Australia; 2 Baker Heart and Diabetes Research Institute, Melbourne, Australia; 3 Department of Cardiology, Royal Melbourne Hospital, Melbourne, Australia



Despite improved understanding of heart failure (HF) and advances in medical treatments, its prevalence continues to rise, and the role of implantable devices continues to evolve. While cardiac resynchronization therapy (CRT) is an accepted form of treatment for many suffering from HF, there is an ever-evolving body of evidence examining novel indications, optimization of lead placement and device programming, with several competing technologies now also on the horizon. This review aims to take a clinical perspective on the major trials, current indications, controversies and emerging aspects of CRT in the treatment of HF.


KEY WORDS: Cardiac resynchronization therapy - Cardiac resynchronization therapy devices - Heart failure - Cardiomyopathies - Prosthesis implantation

top of page